Key highlights from Glenmark Life Sciences Limited (GLS) Q3 FY23 Earnings Concall Q&A Highlights: [00:13:44] Tarang Agrawal of Old Bridge enquired about
Glenmark Life Sciences Limited Q3 FY23 Earnings Conference Call Insights
Categories
Health Care
Torrent Pharmaceuticals Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Management Update: [00:05:39] TORNTPHARM said the company expects to file about
Jyothy Laboratories Limited (JYOTHYLAB) Q3 FY23 Earnings Concall Transcript
Jyothy Laboratories Limited (NSE:JYOTHYLAB) Q3 FY23 Earnings Concall dated Jan. 25, 2023. Corporate Participants: Sanjay Agarwal -- Chief Financial Officer M R Jyothy -- Managing Director
Solara Active Pharma Sciences Limited (SOLARA) Q3 FY23 Earnings Concall Transcript
Solara Active Pharma Sciences Limited (NSE:SOLARA) Q3 FY23 Earnings Concall dated Jan. 25, 2023. Corporate Participants: Abhishek Singhal -- Investor Relations Consultant Jitesh Devendra -- Managing
Torrent Pharmaceutical reports 14% rise in its net profit for Q3FY23
Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to INR 283 crore in the third quarter
Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Transcript
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM) Q3 FY23 Earnings Concall dated Jan. 25, 2023 Corporate Participants: Sudhir Menon -- Executive Director, (Finance) and Chief Financial
Cipla Limited (CIPLA) Q3 FY23 Earnings Concall Transcript
Cipla Limited (NSE: CIPLA) Q3 FY23 Earnings Concall dated Jan. 25, 2023 Corporate Participants: Ankit Bhembre -- Investor Relations Ashish Adukia -- Global Chief Financial Officer
Infographic Ltd.(NSE: DRREDDY) | Q3 FY23 Results | Total Income rises +7.47% qoq
Dr. Reddy's Laboratories (NSE: DRREDDY) is an Indian multinational pharmaceutical company. Founded in 1984, the company primarily develops and sells a wide
Indoco Remedies Limited (INDOCO) Q3 FY23 Earnings Concall Transcript
Indoco Remedies Limited (NSE: INDOCO) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Aditi Panandikar -- Managing Director Sundeep V. Bambolkar -- Joint Managing
Granules India Ltd (GRANULES) Q3 FY23 Earnings Concall Transcript
Granules India Ltd (NSE: GRANULES) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Irfan Raeen -- Investor Relation Advisor Krishna Prasad Chigurupati -- Chairman
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene reported a 5% rise in its net profit for Q3FY23
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Gland Pharma Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Management Update: [00:06:08] GLAND said the insulin line is in the
Shares of Biocon research arm soars as it reports 23% rise in its revenue
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q3 FY23 Earnings Concall dated Jan. 23, 2023. Corporate Participants: Sumanta Bajpayee -- Vice President, Finance and Investor Relations Srinivas
SBI LIFE INSURANCE CO LTD (SBILIFE) Q3 FY23 Earnings Concall Transcript
SBI LIFE INSURANCE CO LTD (NSE: SBILIFE) Q3 FY23 Earnings Concall dated Jan. 21, 2023 Corporate Participants: Mahesh Kumar Sharma -- Managing Director and
Shalby Ltd. Q3FY23; 18% Growth in Profits
Shalby Ltd.‘s revenues in Q3FY23 rose 25% to ₹ 2,067 millions. Consolidated Profit After Tax came at ₹ 153 millions showcasing an
Shalby Limited Q3FY23 Earnings Story
Shalby Ltd. is a leading chain of multispecialty hospitals and tertiary care centers in India. In the Hospital business, the company possesses 11
Apollo Hospitals: Ushering in a New Era
“Our hospital business is on a very strong growth trajectory and will continue to grow. We will improve not only in revenues
Marksans Pharma(NSE:MARKSANS): Everything You Need to Know | Stock up 30% in 3 Months
Marksans Pharma (NSE:MARKSANS) is a mid-sized pharmaceutical company with a large presence in the US, UK, Australia, and New Zealand markets. forward-integrated